Tackling COVID-19 with neutralizing monoclonal antibodies

Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations

(2021) Rakesh Sarkar et al.   ARCHIVES OF VIROLOGY

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

(2021) Robert L. Gottlieb et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

(2021) C. Garrett Rappazzo et al.   SCIENCE

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

(2021) Tyler N. Starr et al.   SCIENCE

Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic

(2021) Lewis F. Buss et al.   SCIENCE

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

(2021) Cheolmin Kim et al.   Nature Communications

Process and Operations Strategies to Enable Global Access to Antibody Therapies

(2021) Brian Kelley et al.   BIOTECHNOLOGY PROGRESS

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

(2021) Emma C. Thomson et al.   CELL

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

(2021) Emma S. Winkler et al.   CELL

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

(2021) Zhuoming Liu et al.   Cell Host & Microbe

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

(2021) Allison J. Greaney et al.   Cell Host & Microbe

Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite

(2021) Gabriele Cerutti et al.   Cell Host & Microbe

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

(2021) Ester C Sabino et al.   LANCET

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

(2021) Dami A. Collier et al.   NATURE

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

(2021) Pengfei Wang et al.   NATURE

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

(2021) Zijun Wang et al.   NATURE

SARS-CoV-2 evolution during treatment of chronic infection

(2021) Steven A. Kemp et al.   NATURE

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

(2021) Rita E. Chen et al.   NATURE MEDICINE

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

(2021) Constantinos Kurt Wibmer et al.   NATURE MEDICINE

Sixteen novel lineages of SARS-CoV-2 in South Africa

(2021) Houriiyah Tegally et al.   NATURE MEDICINE

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

(2021) Ivan O. Rosas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

(2021)   NEW ENGLAND JOURNAL OF MEDICINE

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report

(2021) Kai Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neutralizing Activity of BNT162b2-Elicited Serum

(2021) Yang Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

(2021) Nicholas G. Davies et al.   SCIENCE

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

(2021) Kevin R. McCarthy et al.   SCIENCE

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

(2021) Alexander Muik et al.   SCIENCE

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

(2021) Naveenchandra Suryadevara et al.   CELL

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

(2021) Matthew McCallum et al.   CELL

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

(2021) Xianding Deng et al.   CELL

Antibody evasion by the P.1 strain of SARS-CoV-2

(2021) Wanwisa Dejnirattisai et al.   CELL

Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients – propensity-score matched case-control study

(2021) Adam Tworek et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study

(2021) Dan Frampton et al.   LANCET INFECTIOUS DISEASES

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

(2021) Prabhu S. Arunachalam et al.   NATURE

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

(2021) Sandile Cele et al.   NATURE

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

(2021) Nicholas G. Davies et al.   NATURE

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

(2021) Lawrence Corey et al.   NEW ENGLAND JOURNAL OF MEDICINE

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

(2021) Bryan E. Jones et al.   Science Translational Medicine

Broadly neutralizing antibodies for HIV-1 prevention and therapy

(2021) Boris Julg et al.   SEMINARS IN IMMUNOLOGY

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

(2021) Mark S Graham et al.   Lancet Public Health

A pneumonia outbreak associated with a new coronavirus of probable bat origin

(2020) Peng Zhou et al.   NATURE

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

(2020) Daniel Wrapp et al.   SCIENCE

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

(2020) Michael Letko et al.   Nature Microbiology

A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza A infection

(2020) Jeremy J Lim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

(2020) Alexandra C. Walls et al.   CELL

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

(2020) Rui Shi et al.   NATURE

Human neutralizing antibodies elicited by SARS-CoV-2 infection

(2020) Bin Ju et al.   NATURE

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

(2020) Dora Pinto et al.   NATURE

Developing therapeutic monoclonal antibodies at pandemic pace

(2020) Brian Kelley   NATURE BIOTECHNOLOGY

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

(2020) Meng Yuan et al.   SCIENCE

A human monoclonal antibody blocking SARS-CoV-2 infection

(2020) Chunyan Wang et al.   Nature Communications

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

(2020) Tyler N. Starr et al.   CELL

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

(2020) Qianqian Li et al.   CELL

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells

(2020) Yunlong Cao et al.   CELL

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

(2020) Wafaa B. Alsoussi et al.   JOURNAL OF IMMUNOLOGY

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

(2020) Davide F. Robbiani et al.   NATURE

Potently neutralizing and protective human antibodies against SARS-CoV-2

(2020) Seth J. Zost et al.   NATURE

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

(2020) Ann M. Arvin et al.   NATURE

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

(2020) M. Pamela Griffin et al.   NEW ENGLAND JOURNAL OF MEDICINE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

(2020) Xiangyang Chi et al.   SCIENCE

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

(2020) Alina Baum et al.   SCIENCE

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

(2020) Hongjing Gu et al.   SCIENCE

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

(2020) Thomas F. Rogers et al.   SCIENCE

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

(2020) Johanna Hansen et al.   SCIENCE

Broad neutralization of SARS-related viruses by human monoclonal antibodies

(2020) Anna Z. Wec et al.   SCIENCE

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

(2020) Andrew Rambaut et al.   Nature Microbiology

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy

(2020) Shuo Du et al.   CELL

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

(2020) Luca Piccoli et al.   CELL

Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection

(2020) Stylianos Bournazos et al.   NATURE

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

(2020) Christopher O. Barnes et al.   NATURE

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

(2020) Zunlong Ke et al.   NATURE

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

(2020) Alina Baum et al.   SCIENCE

Neuropilin-1 is a host factor for SARS-CoV-2 infection

(2020) James L. Daly et al.   SCIENCE

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

(2020) Ludovico Cantuti-Castelvetri et al.   SCIENCE

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

(2020) M. Alejandra Tortorici et al.   SCIENCE

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

(2020) Wen Shi Lee et al.   Nature Microbiology

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

(2020) Erik Volz et al.   CELL

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

(2020) Victoria A. Avanzato et al.   CELL

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

(2020) Allison J. Greaney et al.   Cell Host & Microbe

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

(2020) Alexandra Schäfer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Correlates of protection against SARS-CoV-2 in rhesus macaques

(2020) Katherine McMahan et al.   NATURE

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

(2020) Bina Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

(2020) David M. Weinreich et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

(2020) Peter Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study

(2019) Ellie Hershberger et al.   EBioMedicine

Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion

(2019) Alexandra C. Walls et al.   CELL

Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic

(2019) Marina Caskey et al.   NATURE MEDICINE

Novel correlates of protection against pandemic H1N1 influenza A virus infection

(2019) Sophia Ng et al.   NATURE MEDICINE

Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways

(2019) Polina Weitzenfeld et al.   JOURNAL OF CLINICAL INVESTIGATION

A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein

(2019) Aimin Tang et al.   Nature Communications

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

(2019) Sabue Mulangu et al.   NEW ENGLAND JOURNAL OF MEDICINE

How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin

(2018) Michael B. Doud et al.   Nature Communications

Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza

(2018) S. Omar Ali et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

(2018) Pilar Mendoza et al.   NATURE

The influenza virus hemagglutinin head evolves faster than the stalk domain

(2018) Ericka Kirkpatrick et al.   Scientific Reports

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

(2017) Qing Zhu et al.   Science Translational Medicine

Tackling influenza with broadly neutralizing antibodies

(2017) Davide Corti et al.   Current Opinion in Virology

Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes

(2016) Nicole L. Kallewaard et al.   CELL

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection

(2016) David J. DiLillo et al.   JOURNAL OF CLINICAL INVESTIGATION

Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer

(2016) Alexandra C. Walls et al.   NATURE

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1

(2016) T. Schoofs et al.   SCIENCE

Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors

(2016) Daniel F. Ortiz et al.   Science Translational Medicine

The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis

(2014) John Mair-Jenkins et al.   JOURNAL OF INFECTIOUS DISEASES

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

(2014) Sung-Youl Ko et al.   NATURE

Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo

(2014) David J DiLillo et al.   NATURE MEDICINE

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys

(2013) Dan H. Barouch et al.   NATURE

Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab

(2011) Qing Zhu et al.   JOURNAL OF INFECTIOUS DISEASES

Coronaviruses

(2011) Mark R. Denison et al.   RNA Biology

Enhanced antibody half-life improves in vivo activity

(2010) Jonathan Zalevsky et al.   NATURE BIOTECHNOLOGY

Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial

(2009) X. Carbonell-Estrany et al.   PEDIATRICS

Structural characterization of a human Fc fragment engineered for lack of effector functions

(2008) Vaheh Oganesyan et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Palivizumab: where to from here?

(2008) Georgiana Georgescu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY